Clinical Trials Logo

Clinical Trial Summary

A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction


Clinical Trial Description

This study will be conducted in approximately 8 investigational centres in Taiwan. It is expected that approximately 100 patients will be enrolled into study treatment. This study is to describe the safety and tolerability of ticagrelor, by assessment of the bleeding events and other serious adverse events (SAEs) during 1year follow up in Taiwanese non ST-elevation myocardial infarction (NSTEMI) patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02406248
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 4
Start date April 23, 2015
Completion date February 9, 2017

See also
  Status Clinical Trial Phase
Completed NCT02600962 - Impact of Initial Diagnosis on Mortality for Patients Hospitalised With Acute Myocardial Infarction N/A
Completed NCT02436187 - Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study
Completed NCT02693015 - Impact of Time to Coronary Angiography on Survival for NSTEMI N/A